Ranibizumab (a humanized monoclonal fab fragment) is another anti-VEGF agent targeting all VEGF A isoforms approved of wet AMD in 2006 based upon outcomes of ANCHOR and Marina trials with benefits sustaining up to 24 months [81]. The gene discussed is VEGFA; the disease is wet macular degeneration.